# A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction

> **NCT05139615** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 22 (actual)

## Conditions studied

- Acute Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** APD418
- **DRUG:** APD418
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05139615
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-28
- **Primary completion:** 2022-09-19
- **Final completion:** 2022-09-19
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2023-11-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05139615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05139615, "A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05139615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*